Choreo LLC Takes $292,000 Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Choreo LLC purchased a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 22,442 shares of the company’s stock, valued at approximately $292,000.

Other institutional investors have also added to or reduced their stakes in the company. Rise Advisors LLC bought a new position in shares of Takeda Pharmaceutical during the 1st quarter valued at approximately $26,000. Principal Securities Inc. bought a new position in Takeda Pharmaceutical during the fourth quarter valued at $28,000. GAMMA Investing LLC lifted its position in Takeda Pharmaceutical by 50.9% during the first quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock valued at $40,000 after purchasing an additional 966 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Takeda Pharmaceutical by 74.0% in the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after buying an additional 2,330 shares during the last quarter. Finally, Ridgewood Investments LLC purchased a new stake in shares of Takeda Pharmaceutical during the 2nd quarter valued at about $89,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.3 %

TAK opened at $14.85 on Wednesday. The stock has a 50-day moving average of $14.23 and a 200 day moving average of $13.74. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $16.39. The firm has a market cap of $47.25 billion, a P/E ratio of 27.00, a P/E/G ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The firm had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. As a group, research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.